Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.
J Asthma. 2022 Feb;59(2):273-287. doi: 10.1080/02770903.2020.1847927. Epub 2020 Nov 28.
High rates of anxiety and depression exist among asthma patient populations. This scoping review will examine the existing interventional therapies that address depression and anxiety symptoms in patients with asthma.
PubMed, Cochrane, Psychinfo, CINAHL, Google Scholar and EMBASE databases were searched using the following search terms: 'anxiety asthma', 'panic disorder asthma' and 'depression asthma' with a randomized clinical trial filter and additional filters to exclude exclusion criteria.
Study selections included only randomized control trials with anxiety and/or depression and/or panic disorder outcomes as primary or secondary outcomes. Only full-text articles in the English language were included.
This search yielded interventions from pharmacologic ( = 3), psychological ( = 7), lifestyle medicine ( = 10) and complementary and alternative medicine (CAM; = 1) using a range of outcomes from physiologic to psychologic. While the pharmacologic and CAM studies were inconclusive, psychologic and lifestyle interventions showed improvements in asthma (quality of life, symptoms, asthma attacks) and psychological (anxiety, panic fear, depression) outcomes. Variations in selection methods, outcome measures and diagnostic criteria hindered a direct comparison of the studies. Most studies had small sample sizes, high attrition rates and short study durations.
There is limited evidence on best approaches for managing co-morbid anxiety and/or depression in patients with asthma. Psychological and lifestyle medicine interventions are promising with improvements in both asthma and mental health outcomes. Well-designed randomized controlled studies with larger sample sizes, standardized outcomes and longer durations, are needed to better understand the role of depression and anxiety in adults with asthma.
哮喘患者群体中存在较高的焦虑和抑郁发生率。本范围综述将考察现有的干预疗法,以解决哮喘患者的抑郁和焦虑症状。
使用以下搜索词在 PubMed、Cochrane、Psychinfo、CINAHL、Google Scholar 和 EMBASE 数据库中进行搜索:“焦虑哮喘”、“惊恐障碍哮喘”和“抑郁哮喘”,并使用随机临床试验过滤器和其他过滤器排除排除标准。
研究选择仅包括将焦虑和/或抑郁和/或惊恐障碍作为主要或次要结局的随机对照试验。仅纳入全文为英语的文章。
该搜索结果包括来自药理学( = 3)、心理学( = 7)、生活方式医学( = 10)和补充和替代医学(CAM; = 1)的干预措施,使用了从生理到心理的一系列结局。虽然药理学和 CAM 研究没有定论,但心理和生活方式干预显示出对哮喘(生活质量、症状、哮喘发作)和心理(焦虑、惊恐恐惧、抑郁)结局的改善。选择方法、结局测量和诊断标准的差异阻碍了对研究的直接比较。大多数研究的样本量小、失访率高、研究持续时间短。
关于管理哮喘合并症患者共病性焦虑和/或抑郁的最佳方法的证据有限。心理和生活方式医学干预措施有希望,可改善哮喘和心理健康结局。需要进行设计良好的、具有较大样本量、标准化结局和较长持续时间的随机对照研究,以更好地了解抑郁和焦虑在成年哮喘患者中的作用。